Total Funding
24
Total FundingSeed raised
Growth Score
pts
Heat Score
13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
631224
DioGenix develops and commercializes non-invasive diagnostic and prognostic treatment response monitoring tests.
Benjamin M. Greenberg: Chief Medical AdvisorPast Role: Boston Children's Hospital, Deputy Director of the Multiple Sclerosis program
Cam Gallagher: Co-Founder & Board of DirectorsPast Role: Zavante Therapeutics, Co-Founder & Chief Business Officer
Nerveda
About the Company
DioGenix, Inc. engages in the discovery, development, and commercialization of non-invasive diagnostic, prognostic, and treatment response monitoring tests. Its lead program is designed to provide neurologists with a set of clinical tests to diagnose early-stage MS, segment MS patients into clinical sub-types, and predict response to treatment
using non-invasive blood tests. The company was incorporated in 2007 and is based in Gaithersburg, Maryland. As of September 19, 2008, DioGenix, Inc. operates as a subsidiary of Nerveda, Inc.
